Carbohydrate metabolism and the liver: Actual aspects from physiology and disease

Zeitschrift fur Gastroenterologie

Volumn 45, Issue 1, 2007, Pages 51-62

  Raddatz, D ^a   Ramadori, G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Hepatic glucose production; Hepatitis C; Hepatogenous diabetes; IGF 1; Insulin; Insulin resistance; NAFLD

Indexed keywords

ADIPOCYTOKINE; CARBOHYDRATE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GROWTH HORMONE; INSULIN; INTERLEUKIN 6; LEPTIN; RESISTIN; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME REGULATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CELL; LIVER DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CARBOHYDRATE METABOLISM; DIETARY CARBOHYDRATES; GLUCOSE; HUMANS; INSULIN RESISTANCE; LIVER; LIVER DISEASES; MODELS, BIOLOGICAL;

EID: 33846783238     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-927394     Document Type: Review

References (137)

1. Rothman DL, Magnusson I, Katz LD et al. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991; 254: 573-576
2. Toffolo G, Campioni M, Basu R et al. A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab 2006; 290: E169-E176
3. Giacca A, Fisher SJ, Shi ZQ et al. Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. J Clin Invest 1992; 90: 1769-1777
4. Lewis GF, Zinman B, Groenewoud Y et al. Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes 1996; 45: 454-462
5. Ferrannini E, Galvan AQ, Gastaldelli A et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999; 29: 842-852
6. Duong DT, Waltner-Law ME, Sears R et al. Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem 2002; 277: 32 234-32 242
7. Hall RK, Yamasaki T, Kucera T et al. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. J Biol Chem 2000; 275: 30 169-30 175
8. O'Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev 1996; 76: 1109-1161
9. Lewis GF, Vranic M, Giacca A. Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans. Am J Physiol 1998; 275: E177-E186
10. Obici S, Zhang BB, Karkanias G et al. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002; 8: 1376-1382
11. Cherrington AD, Edgerton D, Sindelar DK. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia 1998; 41: 987-996
12. Sindelar DK, Chu CA, Venson P et al. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 1998; 47: 523-529
13. Edgerton DS, Lautz M, Scott M et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006; 116: 521-527
14. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 2003; 111: 463-468
15. Okamoto H, Obici S, Accili D et al. Restoration of liver insulin signaling in lnsr knockout mice fails to normalize hepatic insulin action. J Clin Invest 2005; 115: 1314-1322
16. Michael MD, Kulkarni RN, Postic C et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97
17. Buettner C, Patel R, Muse ED et al. Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice. J Clin Invest 2005; 115: 1306-1313
18. Cherrington AD. The role of hepatic insulin receptors in the regulation of glucose production. J Clin Invest 2005; 115: 1136-1139
19. Girard J. Insulin's effect on the liver: "direct or indirect?" continues to be the question. J Clin Invest 2006; 116: 302-304
20. Jungermann K, Gardemann A, Beuers U et al. Regulation of liver metabolism by the hepatic nerves. Adv Enzyme Regul 1987; 26: 63-88
21. Pocai A, Obici S, Schwartz GJ et al. A brain-liver circuit regulates glucose homeostasis. Cell Metab 2005; 1: 53-61
22. Magnusson I, Rothman DL, Katz LD et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-1327
23. Reaven GM, Chen YD, Golay A et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106-110
24. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992; 54: 885-909
25. Sun Y, Liu S, Ferguson S et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem 2002; 277: 23 301-23 307
26. Trinh KY, O'Doherty RM, Anderson P et al. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem 1998; 273: 31 615-31 620
27. Barzilai N, Rossetti L. Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin. J Biol Chem 1993; 268: 25 019-25 025
28. Burchell A, Cain DI. Rat hepatic microsomal glucose-6-phosphatase protein levels are increased in streptozotocin-induced diabetes. Diabetologia 1985; 28: 852-856
29. Valera A, Pujol A, Pelegrin M et al. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994; 91: 9151-9154
30. Christ B, Nath A, Bastian H et al. Regulation of the expression of the phosphoenolpyruvate carboxykinase gene in cultured rat hepatocytes by glucagon and insulin. Eur J Biochem 1988; 178: 373-379
31. Yoon JC, Puigserver P, Chen G et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001; 413: 131-138
32. Puigserver P, Rhee J, Donovan J et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555
33. Christ B, Yazici E, Nath A. Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes. Hepatology 2000; 31: 461-468
34. Metzger S, Goldschmidt N, Barash V et al. Interleukin-6 secretion in mice is associated with reduced glucose-6-phosphatase and liver glycogen levels. Am J Physiol 1997; 273: E262-E267
35. Inoue H, Ogawa W, Ozaki M et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168-174
36. Dentin R, Pegorier JP, Benhamed F et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004; 279: 20 314-20 326
37. Dentin R, Benhamed F, Hainault I et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006; 55: 2159-2170
38. Valera A, Bosch F. Glucokinase expression in rat hepatoma cells induces glucose uptake and is rate limiting in glucose utilization. Eur J Biochem 1994; 222: 533-539
39. Ferre T, Riu E, Bosch F et al. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J 1996; 10: 1213-1218
40. Ferre T, Pujol A, Riu E et al. Correction of diabetic alterations by glucokinase. Proc Natl Acad Sci USA 1996; 93: 7225-7230
41. Yakar S, Liu JL, Fernandez AM et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50: 1110-1118
42. Fernandez AM, Kim JK, Yakar S et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001; 15: 1926-1934
43. Haluzik M, Yakar S, Gavrilova O et al. Insulin resistance in the liver-specific IGF-1 gene-deleted mouse is abrogated by deletion of the acid-labile subunit of the IGF-binding protein-3 complex: relative roles of growth hormone and IGF-1 in insulin resistance. Diabetes 2003; 52: 2483-2489
44. Yakar S, Setser J, Zhao H et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004; 113: 96-105
45. O'Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 2002; 87: 4356-4360
46. Desbriere R, Vuaroqueaux V, Achard V et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006; 14: 794-798
47. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170
48. Paulsen SK, Pedersen SB, Jorgensen JO et al. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 2006; 91: 1093-1098
49. Thieringer R, Hermanowski-Vosatka A. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids playa role? Expert Rev Cardiovasc Ther 2005; 3: 911-924
50. Wang M. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs 2006; 7: 319-323
51. Naunyn B. Glycosurie und Diabetes durch experimentelle Insulte und Krankheiten der Leber. In: E. N (Hrsg). Handbuch Spez Path Terap. Wien: A. Holder, 1898: 38-49
52. Buzzelli G, Chiarantini E, Cotrozzi G et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver 1988; 8: 354-359
53. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970; 3: 371-407
54. Gentile S, Turco S, Guarino G et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab 2001; 3: 33-40
55. Holstein A, Hinze S, Thiessen E et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-681
56. Bianchi G, Marchesini G, Zoli M et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-125
57. Vannini P, Forlani G, Marchesini G et al. The euglycemic clamp technique in patients with liver cirrhosis. Horm Metab Res 1984; 16: 341-343
58. Muller MJ, Willmann O, Rieger A et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology 1992; 102: 2033-2041
59. Kruszynska Y, Williams N, Perry M et al. The relationship between insulin sensitivity and skeletal muscle enzyme activities in hepatic cirrhosis. Hepatology 1988; 8: 1615-1619
60. Taylor R, Heine RJ, Collins J et al. Insulin action in cirrhosis. Hepatology 1985; 5: 64-71
61. Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 1995; 103: 63-74
62. Siegel EG, Seidenstucker A, Gallwitz B et al. Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1. J Endocrinol 2000; 164: 13-19
63. Misbin RI, Merimee TJ, Lowenstein JM. Insulin removal by isolated perfused rat liver. Am J Physiol 1976; 230: 171-177
64. Navalesi R, Pilo A, Ferrannini E. Insulin kinetics after portal and peripheral injection of (125I) insulin: II. Experiments in the intact dog. Am J Physiol 1976; 230: 1630-1636
65. Kruszynska YT, Home PD, McIntyre N. Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis. Hepatology 1991; 14: 103-111
66. Raddatz D, Rossbach C, Buchwald A et al. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS). Exp Clin Endocrinol Diabetes 2005; 113: 268-274
67. Perseghin G, Mazzaferro V, Sereni LP et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000; 31: 694-703
68. White MF. The insulin signalling system and the IRS proteins. Diabetologia 1997; 40 (Suppl 2): S2-17
69. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol 2002; 12: 65-71
70. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80
71. Aguirre V, Werner ED, Giraud J et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-1537
72. Lin Y, Berg AH, Iyengar P et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005; 280: 4617-4626
73. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761
74. Ozcan U, Cao Q, Yilmaz E et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461
75. Ozawa K, Miyazaki M, Matsuhisa M et al. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes 2005; 54: 657-663
76. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-948
77. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336
78. Gao Z, Zhang X, Zuberi A et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 2004; 18: 2024-2034
79. Yu C, Chen Y, Cline GW et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50 230-50 236
80. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/ NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S49-52
81. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190
82. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769
83. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-737
84. Bugianesi E, Pagotto U, Manini R et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-3504
85. Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54
86. Xu A, Wang Y, Keshaw H et al. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100
87. Kaser S, Moschen A, Cayon A et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121
88. Kaser S, Foger B, Waldenberger P et al. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. J Hepatol 2000; 33: 902-906
89. Harle P, Straub RH. Leptin is a link between adipose tissue and inflammation. Ann N Y Acad Sci 2006; 1069: 454-462
90. Petersen KF, Oral EA, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350
91. Aleffi S, Petrai I, Bertolani C et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 1339-1348
92. Leclercq IA, Farrell GC, Schriemer R et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-213
93. McCullough AJ, Bugianesi E, Marchesini G et al. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998; 115: 947-953
94. Nolte W, Wirtz M, Rossbach C et al. TIPS implantation raises leptin levels in patients with liver cirrhosis. Exp Clin Endocrinol Diabetes 2003; 111: 435-442
95. Liangpunsakul S, Chalasani N. Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol 2004; 38: 891-897
96. Bethanis SK, Theocharis SE. Leptin in the field of hepatic fibrosis: A pivotal or an incidental player? Dig Dis Sci 2006; Epub ahead of print. doi: 10.1007/s10620-006-9126-0
97. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
98. Rajala MW, Qi Y, Patel HR et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679
99. Rangwala SM, Rich AS, Rhoades B et al. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941
100. Rajala MW, Obici S, Scherer PE et al. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111: 225-230
101. Muse ED, Obici S, Bhanot S et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004; 114: 232-239
102. Way JM, Gorgun CZ, Tong Q et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276: 25 651-25 653
103. Engeli S, Bohnke J, Feldpausch M et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004; 12: 9-17
104. Patel K, Muir A, McHutchison JG et al. A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. Am J Gastroenterol 2003; 98: 952-955
105. Savage DB, Sewter CP, Klenk ES et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202
106. McTernan CL, McTernan PG, Harte AL et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47
107. McTernan PG, McTernan CL, Chetty R et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002; 87: 2407
108. Lin SY, Sheu WH, Chen WY et al. Stimulated resistin expression in white adipose of rats with bile duct ligation-induced liver cirrhosis: relationship to cirrhotic hyperinsulinemia and increased tumor necrosis factor-alpha. Mol Cell Endocrinol 2005; 232: 1-8
109. Yagmur E, Trautwein C, Gressner AM et al. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006; 101: 1244-1252
110. Bahr MJ, Ockenga J, Boker KH et al. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-206
111. Pagano C, Soardo G, Pilon C et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91: 1081-1086
112. Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668
113. Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614
114. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350
115. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850
116. Fernandez-Real JM, Vayreda M, Richart C et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001; 86: 1154-1159
117. Andreozzi F, Laratta E, Cardellini M et al. Plasma interleukin-6 levels are independently associated with insulin secretion in a cohort of Italian-Caucasian nondiabetic subjects. Diabetes 2006; 55: 2021-2024
118. Di Gregorio GB, Hensley L, Lu T et al. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 2004; 287: E182-187
119. Wallenius V, Wallenius K, Ahren B et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79
120. Allison ME, Wreghitt T, Palmer CR et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139
121. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599
122. Mangia A, Schiavone G, Lezzi G et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol 1998; 93: 2363-2367
123. Shaheen M, Echeverry D, Oblad MG et al. Hepatitis C, metabolic syndrome, and inflammatory markers: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Res Clin Pract 2006; Epub ahead of print. doi: 10.106/j.diabres.2006.07.008
124. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression (corrected). Gastroenterology 2003; 125: 1695-1704
125. Tazawa J, Maeda M, Nakagawa M et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-715
126. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848
127. Tsutsumi T, Suzuki T, Moriya K et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002; 304: 415-424
128. Aytug S, Reich D, Sapiro LE et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1892
129. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455
130. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850
131. Kraegen EW, Clark PW, Jenkins AB et al. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991; 40: 1397-1403
132. Kim JK, Fillmore JJ, Chen Yet al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001; 98: 7522-7527
133. Friedman J. Fat in all the wrong places. Nature 2002; 415: 268-269
134. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-434
135. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000
136. Tiikkainen M, Hakkinen AM, Korsheninnikova E et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176
137. Matsumoto M, Han S, Kitamura T et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006; 116: 2464-2472